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THE ISOLATION OF A STAPHYLOCOCCUS HOMINIS
STRAIN WITH DECREASED SUSCEPTIBILITY TO
VANCOMYCIN FROM A MULTIPLE-ANTIMICROBIAL
TREATED IMMUNOSUPRESSED PATIENT
Doufexis D1, Kosmopoulou O2, Greka P1*, Stefanou
I3, Avlami A3, Panayiotidis P1, Daikos GL1; 11st Dpt
of Propedeutic Medicine, Athens University Med-
ical School; 21st Dpt of Internal Medicine,‘‘Agios
Panteleimon’’ General Hospital; 3Dpt of Microbiol-
ogy, ‘‘Laikon’’ General Hospital
We report the ﬁrst case of infection caused by a
staphylococcal strain with decreased susceptibility
to glycopeptides in Athens, Greece. It concerns a
74 year-old male patient diagnosed with myelodys-
plastic syndrome (RAEB) in May 2003 who was
admitted to our unit because of fever of unknown
origin since January 2004, not attributed to his
underlying hematological disease.
The patient was treated with ﬁlgrastim (G-CSF)
subcutaneous injections thrice weekly and also
16mg methylprednisolone pos for an 8 month pe-
riod before his admission to our hospital due to
concurrent autoimmune haemolytic anemia. His
absolute neutrophil count was always >1000/l
and his total serum IgG was equal to 2.4 g/dl with-
out evidence of monoclonal component(s).
During the time of his diagnostic evaluation,
the patient was simultaneously receiving multiple
courses of empirical antimicribial treatments (2nd
generation cephalosporins, quinolones) to which
he had never responded, whereas ciproﬂoxacin
was also provided as part of an empirical qua-
triple antituberculous regimen. Between 11/2 and
25/2/04 he was treated with ampicillin (24 gr/day)
and imipenem (3 gr/day) because of the isolation
from both blood (6 out of 6) and urine of a highly
aminoglycoside-resistant Enterococcus faecalis
strain. This ﬁnding was soon followed by positive
blood cultures with a methicillin-resistant Staphy-
lococcus coagulase-negative strain (Staphylococ-
cus hominis) for which the patient was treated
with vancomycin (1 gr bid, iv) without concomi-
tant evaluation of blood levels of the drug. On the
tenth day of this treatment the blood cultures be-
came again positive with the same staphylococcal
strain (without evidence of a deep seated infec-
tion or endocarditis) which was still being reported
as vancomycin-susceptible (MIC = 1g/ml) with
the usual laboratory sensitivity techniques. How-
ever, because of the discordance between clinical
and laboratory data, the NCCLS suggested meth-
ods of vancomycin susceptibility were employed
(vancomycin-enriched agar, E-test) by which the
MIC of the strain to vancomycin and teicoplanin
were found tequal to 4 and 16g/ml correspond-
ingly (desusceptibility to glycopeptides). Ever
since, the patient was provided monotherapy with
linezolid.
This is the ﬁrst report of decreased susceptibility
in staphylococcal strains in Greece and it must be
connected to the previous use of multiple antimi-
crobials. Physicians should be aware of this emerg-
ing problem mainly in areas with a high incidence
of MRSA strains.
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PROFILE OF OPPORTUNISTIC INFECTIONS AMONG
PATIENTS ON IMMUNOSUPPRESSIVE MEDICATION
Wanchu A*, Reddy S, Gupta V, Bambery P; Depart-
ments of Internal Medicine and Ophthalmology,
PGIMER, Chandigarh, India
OBJECTIVES: The widespread use of immunosup-
pressives in treating systemic autoimmune disor-
ders has resulted in an increase in opportunistic
infections (OI’s) in patients undergoing such treat-
ment. We carried out this study to analyze the
proﬁle of OI’s requiring hospitalization in patients
being treated with glucocorticoids and other im-
munosuppressive agents as part of management of
systemic autoimmune disorders and to analyze the
host factors in relation to the OI’s.
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MATERIALS & METHODS: We studied all patients hos-
pitalized in PGIMER undermedical units for OI’s that
occurred following and during treatment with corti-
costeroids and other immunosuppressive agents for
treatment of systemic autoimmune disorders from
February 2002 to January 2003. The control group
were patients with autoimmune uveitis and under
treatment in the Ophthalmology out patient de-
partment with steroids or other immunosuppressive
agents and had a follow up of one year or more. All
relevant details were recorded in a standard per-
forma.
RESULTS: Nineteen patients (16 females) were ad-
mitted because of OI’s. Control group included 22
males and 11 females. The mean age (+S.D.) in
case group was 37.32 (+19.9) years and in control
group 34.22 (+14.62) years. Ten patients with had
SLE, 2 had SLE with overlap, 5 had rheumatoid
arthritis, and 1 each had vasculitis and scleroderma
with polymyositis. There were 28 infections. One
(5.3%) patient had 4 infections, 1 (5.3%) had 3
infections, 6 (31.6%) of them had 2 infections, 9
(47.4%) had 1 infection and in 2 (10.5%) patients
the infection was not localized. In the control group
none had an OI over a period of one year. Of the 19
cases, 10 (52.6%) received prednisolone in a dose
>10mg/day, with the median dose of 1130mg.
Nine (47.4%) were on prednisolone <10mg/day
with median dosage of 880mg. All control group
patients received >10mg/day of prednisolone.
Methyl prednisolone was given to 2 (6.3%) patients
in the control and 1 (5.3%) patient in the case group
(p value 0.9). Bacteria accounted for most of the
infections. There were two fungal infections and 1
each patient with tuberculosis and peritonitis. In-
fections occurred predominantly in the chest, urine
and skin. Septicemia was diagnosed in three pa-
tients. There were two deaths, one each with SLE
and RA.
CONCLUSION: The absence of infections in the con-
trol group and comparison of these with the patient
group suggest that the systemic autoimmune disor-
ders may be, per se, responsible for an increased
risk of infections.
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TUBERCULOSIS IN THE IMMUNOCOMPROMISED
HOSTS
He Bei*, Wang Fei; Pulmonary Division, Peking Uni-
versity Third Hospital, Beijing, PR China
OBJECTIVE: TB is a common pulmonary infectious
disease in Chinese population. It becomes more
complex when it occurs in an immunocompromised
status. Proper treatment will be delayed if correct
diagnosis can’t be made promptly. The patients
with connective tissue diseases (CTD) and TB were
investigated to ﬁnd clinical ﬁgures in these patients
to better understand TB in immunocompromised
hosts.
METHODS: From 1994 to 2003, 824 TB cases were ad-
mitted in our hospital, and treated for either main
disease or combined disease. 230 cases were diag-
nosed as other diseases than TB on entry into our
hospital. Nineteen of them had CTD and active TB.
TB was diagnosed either by bacteria test in sputum
or lung biopsy.
RESULTS: Twelve of 19 were collected because
of having complete data. Two males and 10 fe-
males were collected, mean age 51.5 yrs. in males
and 43 yrs. in females. CTD had been diagnosed
as following: 6 cases with SLE, 4 with rheuma-
toid arthritis, one with Sjogren’s syndrome and
one with mixed connective tissue disease (MCTD).
Fever was seen in 11 cases (91.67%), 39.1—41; in
9 (75%), 38.1—39.0; in one (8.3%) and <38.0; in
one (8.3%). No one had night sweating and weigh
loss. Five of 12 had fatigue. Lung abnormal signs
were found in 7 of 12 (58.3%), including dry and
moist rales. Eight of 12 were treated with antibi-
otics before TB diagnosed (66.7%). Minimal dose of
prednison was 10mg per day. The temperature was
decreased a little only in one case. The mean time
from onset of TB to diagnosis was 55 days, includ-
ing the days before entered the hospital. Eight of
12 had history of taking immunosuppressive drugs
for a long time (66.7%). Respiratory TB was seen
in 11 of 12 (91.6%), including miliary TB in 3 (2 of
3 were found in patients with SLE), secondary TB
in 5, and TB pleurisy in 3. The extra-pulmonary TB
was diagnosed in one case. TB antibody test was
performed in 5, one of them was positive (20%).
PPD test was done in 7, but positive result only in
one case (14.28%). They were treated with antitu-
berculosis drugs (Rifampin, Isoniazid, Ethambutol
with or without Pyrazina) after being diagnosed.
Nine cases had very good response, temperature
returning to normal within one week after anti-
tuberculosis treatment. Two cases had some re-
sponse. One patient with miliary TB died from
ARDS.
CONCLUSION: Combined TB was not very com-
mon in the patients with CTD even taking steroid.
It seems that TB was more common in women
with CTD than men in our study. High fever was
seen in most cases. In this patient group, mili-
tary TB was more commonly seen in the patients
with SLE than other CTD. The extra-pulmonary
TB needs to be considered although TB in respi-
ratory system was more found in these patients.
Lung biopsy is valuable to make diagnosis some-
time.
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HUMAN HERPESVIRUS-8 CAN BE ACTIVATED BY
CORTICOSTEROIDS?
Magira E*, Gounaris T, Gounari P, Sioula E; 1st De-
partment of Internal Medicine, Evangelismos Hos-
pital Athens Greece
We report two cases of Kaposi’s sarcoma in 2 pa-
tients after receiving corticosteroid therapy. A
73-year-old woman was admitted to our hospital in
June 2002 because of painful disseminated lesions
on the limbs along with multiple papules and hard
nodules on her lower abdomen and neck that were
red violent to brown without tendency to ulcera-
tion. The lesions were appeared a year ago. Be-
cause of rheumatoid arthritis, she had been treated
with methyprednisolone 16mg per day since 1999.
Biopsy excision was performed and showed vascular
proliferation and ‘‘sarcoma like’’ spindle cell for-
mation that suggested Kaposi’s sarcoma (KS). HIV
test by Elisa andWestern blot analysis was negative.
Furthermore the patient showed abnormalities in
the level of immunoglobulins and the composition
of T lymphocytes with a reversed ratio of CD4 to
CD8 cells. A 70-year-old-man was admitted to our
hospital as well with several weeks’ history of dys-
pnea due to right side pleural effusion along with
few solitary nodules in the lung parenchyma with
a basal predilection. The patient’s chest radio-
graphic features were very consistent with intersti-
tial lung disease possibly due to collagen vascular
disorder and he was placed on methylprednizolone
16mg twice daily. Extensive and multiple labora-
tory tests rule out infection or neoplastic diseases.
On physical examination we noticed disseminated
skin lesions on the limbs, sole, hands and face.
The lesions were hard nodules and inﬁltrates, red
violent to brown without tendency to ulceration.
respiratory function. Dermatological examination
revealed painful hard nodules and inﬁltrates that
were red violent to brown without tendency to ul-
ceration. HIV test by Elisa and Western blot analysis
was negative. Biopsy excision was performed and
the histopathological picture suggested Kaposi’s
sarcoma. Peripheral blood mononuclear cells were
tested positive for Human Herpes Virus 8 (HHV 8) by
PCR and immunohistochemistry of the tissue. HHV 8
is a herpesvirus resulting in Kaposi’s sarcoma (KS).
Furthermore the patient showed abnormalities in
the level of immunoglobulins and the composition
of T lymphocytes with a reversed ratio of CD4 to
CD8 cells. In the literature, there have been about
10 cases-to our knowledge-reported that had been
treated with corticosteroid and developed Kaposi’s
sarcoma; therefore, immunosupression induced by
corticosteroid is a possible risk factor for the trig-
gering of the HHV8 and the development of KS,
probably in genetically susceptible patients. Hu-
man herpesvirus 8 (HHV8) has been identiﬁed as
the causative factor in Kaposi’s sarcoma and has
been also detected in classic KS, endemic African
KS and tranplantation-related KS. HHV8-infected T
cells and monocytes might be responsible for the
circulation of HHV8 and the multicentic nature of
the KS lesions.
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PRECLINICAL EVALUATION OF ENTEROSTIM-M40
VACCINE IN CONJUNCTION WITH PANCREATIC
BETA-CELLS IN ANIMALSWITH DIABETES MELLITUS
Dima FV2, Balotescu C, Flueras M2, Ionescu MD,
Ionescu P, Dima VS2; Cantacuzino Institute, 2Central
Military Hospital, Bucharest, Romania Unione Sani-
taria Internationale, Rome, Italy
BACKGROUND & OBJECTIVES: The present study
was undertaken to evaluate the effectiveness of
mucosal immunization with Enterostim-M40 vac-
cine entrapped in liposomes associated with pan-
creatic beta-cells in diabetic animals.
STUDY DESIGN/MATERIALS & METHODS: Ten days
after streptozocyn inoculation (60mg/kg body
weight), diabetic animals received intraperitoneal
injections with puriﬁed pancreatic beta-cells
(2.5× 109 cells/animal). Seven days later both di-
abetic and healthy inbred rats were immunized
by mucosal route with two doses of Enterostim-40
(multi-component vaccine prepared from the
main enteric pathogens) (140g/dose/animal) ﬁve
days apart. Twelve and twenty-four days after
the last dose of Enterostim-M40, Peyer’s patches
T-lymphocytes were obtained from the small intes-
tine.
MAIN RESULTS: (a) Intraperitoneal inoculation of
puriﬁed beta-cells improved pancreatic parameters
for 4—6 weeks after islets implantation in 25 of 36
recipients (69.4%); (b) The Enterostim-M40 vaccine
was protective against oral challenge with 3.5× 106
virulent cells of enterotoxigenic E. coli H10407
strain; (c) the administration of Enterostim-M40
in conjunction with pancreatic beta-cells was not
reactogenic and promoted marked immunity as
shown mucosal (slgA) and cell mediated immunity
(assayed by the 3H-Thymidine uptake by Peyer’s
patches T lymphocytes. The metabolic histopatho-
logical, bacteriological and electron microscopy
ﬁndings conﬁrm the above results.
CONCLUSIONS: The results of this study point out:
(1) The normalization of metabolic parameters;
(2) The Enterostim-M40 vaccine in conjunction
with pancreatic beta-cells induces augmentation
of mucosal and cell-mediated immunity; (3) the
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experimental results suggest that the associated
therapy can be used in prevention of intestinal in-
fections caused by enterotoxigenic Escherichia coli
strains (ETEC) in animals with diabetes mellitus.
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DAPTOMYCIN FOR THE TREATMENT OF cSSSI IN IM-
MUNOCOMPROMISED HOSTS
Baird IM*; Riverside Methodist Hospital, Columbus,
Ohio
OBJECTIVE: Immunocompromised patients are at
greater risk for serious infections than immuno-
competent patients and present unique treatment
challenges. Daptomycin is a new, mechanisti-
cally distinct, anti-Gram-positive agent that is
rapidly bactericidal in vitro. Two large, random-
ized, investigator-blinded clinical trials compared
daptomycin (4mg/kg IV q 24) with conventional
antibiotics (penicillinase-resistant semisynthetic
penicillins [SSP] 4—12 g/day IV or vancomycin 1 g
q12h IV) in the treatment of complicated skin and
skin structure infections (cSSSI).
METHODS: Based on clinical evaluation, subjects
were assigned to SSP or vancomycin groups. Each
group was then randomized to receive either dapto-
mycin or appropriate comparator. Immunocompro-
mised patients comprised 3% of the intent-to-treat
population, according to investigator assessment
at baseline evaluation (N = 37). Patients were
expected to receive only IV therapy; however, a
change to oral medication was permitted after at
least 4 days of IV therapy if there had been clear
clinical improvement and the infecting organism
was susceptible to an available oral therapy.
RESULTS: For the clinically evaluable population,
clinical success rates were 76.9% (10/13) and 60%
(9/15) for daptomycin- and comparator-treated
patients, respectively (95% CI, −50.7, 16.8). Within
each prerandomized cohort, success rates were
100% (2/2) and 50% (4/8) for daptomycin- and
vancomycin-treated patients and 77.8% (7/9) and
71.4% (5/7) for daptomycin- and SSP-treated pa-
tients, respectively. Among immunocompromised
patients successfully treated with IV therapy
alone, median duration of therapy was shorter for
daptomycin-treated patients (7 days [N = 8]) than
comparator-treated patients (10 days [N = 7]).
Similarly, among all successfully treated, clin-
ically evaluable, immunocompromised patients
(including those who received oral antibiotics),
total days on treatment (IV + oral) was shorter
for daptomycin-treated patients (median 7.5 days;
mean 9.6 days ±SD 3.6; range 7—17 days [N = 10])
than for comparator-treated patients (median 10
days; mean 12.1 days ±SD 6.9; range 6—29 days
[N = 9]). Safety was evaluated in 37 (18 dap-
tomycin; 19 comparator) immunocompromised
patients who received at least 1 dose of study
medication. Adverse events (AEs) were mostly
mild to moderate in intensity. At least 1 AE was
experienced by 8 of 18 (44%) daptomycin-treated
patients, of which 3 were considered possibly or
probably drug-related, compared with 15 of 19
(79%) comparator-treated patients, of which 6
were considered possibly or probably drug-related.
Gastrointestinal disorders represented the most
frequent category of AE in both groups. Eight pa-
tients experienced serious AEs (2 daptomycin;
6 comparator), none of which were considered
related to study drug.
CONCLUSION: Overall, the safety and efﬁcacy of
daptomycin were comparable with conventional
therapy in the treatment of cSSSI in immunocom-
promised hosts. Patients treated with daptomycin
required fewer days of total therapy (IV + oral) and
IV therapy alone than comparator-treated patients.
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SUCEPTIBILITY OF ANAEROBIC BACTERIA ISO-
LATED FROM IMMUNOCOMPROMISED PATIENTS TO
ANTIMICROBIAL AGENTS IN BULGARIA
Marina M*, Ivanova K; Anaerobic Laboratory, Na-
tional Center of Infectious and Parasitic Diseases,
Soﬁa, Bulgaria
The antimicrobial susceptibility of anaerobic bac-
teria isolated from immuno-compromised patients
with anaerobic infections was followed for a period
of 20 years, 1983—2003. The study was carried out
in the referent for Bulgaria anaerobic laboratory.
NCCLS - recommended agar dilution methods were
used. -lactamase activity was determined with ni-
troceﬁn discs. The 29 antimicrobial agents included
in the study were divided according to their in vitro
activity against the anaerobic isolates into 4 main
groups:
1st group - of metronidazole, chloramphenicol,
meropenem, imipenem and combinations of
-lactam antibiotics with sulbactam - with high
activity and drugs of choice for treatment;
2nd group - clindamycin, cefoxitin, carbeni-
cillin/and azlocillin, piperacillin/- with a good
activity and low percent of resistant strains;
3rd group - of tetracycline and erythromycin with
higher percent of resistant strains including the
new macrolides as josamycin, clarithromycin,
roxithromycin and azithromycin;
4th group - penicillins/ampicillin, amoxicillin,
penicillin/ and cephalosporins/cefamandole,
cefazolin, cefotaxime and cefoperazone/- not
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suitable for treatment of infections including
Bacteroides fragilis group strains, with a very
high percent of resistant strains, probably due
to -lactamase activity in most of the strains.
The results of this long-term study can be an ex-
cellent tool for clinicians in our country in guiding
the empirical treatment of those often severe, life
threatening and with a quick development infec-
tions, caused by anaerobes, especially in immuno-
compromised patients.
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A PILOT STUDY IN HIGH RISK UNITS OF A TERTIARY
CARE HOSPITAL TO DEVELOP A CLINICALLY RELE-
VANT ESBL TESTING PROTOCOL
Guleri A*, Alcock SR, Corcoran GD, Samavedam S,
Robinson J, Wilson J; Department of Clinical Micro-
biology, Western Inﬁrmary, North Glasgow Univer-
sity Hospitals NHS Trust
OBJECTIVES: Detection of extended spectrum
-lactamase (ESBL) and AmpC -lactamase (AmpC)
producing Gram-negative rods (GNR) in a clinically
relevant time frame is a growing concern for hospi-
tal laboratories. Lack of consensus on optimal test
protocols and interpretive guidelines for species
other that Esch. coli and Klebsiella spp. complicates
the issue for clinical laboratories, where molecular
methods are not readily available. We examined
various phenotypic methods of ESBL/AmpC detec-
tion to develop an optimal protocol.
METHODS: 72 cefotaxime and/or ceftazidime re-
sistant [NCCLS] GNR from clinical specimens (from
renal transplant, oncology, haematology units and
ITU/HDU) were tested for ESBL/Amp-C production
using NCCLS, manufacturer’s guidelines and current
literature.
ESBL detection: Three test panels included ESBL
E-test (AB Biodisk) panel (cefepime, ceftazidime
and cefotaxime, each ± clavulanic acid), conven-
tional combination disc panel (cefpodoxime, cef-
tazidime and cefotaxime, each ± clavulanic acid)
and an extended panel (cefpirome and cefepime,
each± clavulanic acid. Cefoxitin disc used for AmpC
detection.
RESULTS: ESBLs and/or AmpC were detected in
all of the 72 isolates tested; 20 were positive for
ESBL only, 23 for AmpC only and 29 for both. The
distribution of positive results with pictures dis-
cussed. The isolates were Enterobacter cloacae
(25), E.coli (14), Klebsiella pneumoniae (12), Ser-
ratia marcescens and Citrobacter freundii (4 each),
Serratia liquefaciens (3), Citrobacter koserii, Mor-
ganella morganii, Salmonella virchow (2 each),
Citrobacter youngae and Enterobacter aerogenes
(1 each).
CONCLUSIONS: Use of more than one substrate for
screening, and a combination of ESBL combina-
tion discs including cefepime or cefpirome [each ±
clavulanic acid] for conﬁrmation appears to make
ESBL testing with discs more sensitive. ESBL E-test
strips are simpler to use and almost as sensitive as
the combination of discs.
